Bridgebio Oncology Therapeutics, Inc. (BBOT)
4.71
-0.06
(-1.26%)
USD |
NASDAQ |
Sep 21, 11:12
Bridgebio Oncology Therapeutics Shareholders Equity (Quarterly) : 323.11M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 323.11M |
| March 31, 2026 | 372.28M |
| December 31, 2025 | 411.10M |
| September 30, 2025 | 446.70M |
| June 30, 2025 | 189.24M |
| March 31, 2025 | 188.29M |
| Date | Value |
|---|---|
| December 31, 2024 | 144.72M |
| September 30, 2024 | 186.69M |
| June 30, 2024 | 184.28M |
| March 31, 2024 | 181.99M |
| December 31, 2023 | -0.0636M |
| December 31, 2022 | -0.0219M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 376.71M |
| Total Liabilities (Quarterly) | 53.59M |
| Debt to Equity Ratio | 0.0078 |
| Current Ratio | 4.694 |
| Net Debt Paydown Yield | -0.08% |